RISK MARKERS FOR CARDIOVASCULAR DISEASE IN YOUNG TYPE 1 DIABETIC PATIENTS: LIPOPROTEINS, HIGH-SENSITIVITY C-REACTIVE PROTEIN AND ADIPONECTIN

REFERENCES

• Dorchy H. Screening for subclinical complications in young type 1 diabetic patients: experience acquired in Brussels. Pediatr Endocrinol Rev 2004; 1: 380–403.
   Google Scholar
• Willems D, Dorchy H, Dufrasne D. Serum lipoprotein (a) in type 1 diabetic chil-dren and adolescents: relationships with HbA1c and subclinical complications. Eur J Pediatr 1996; 155: 175–178.
   PubMed Web of Science ®Google Scholar
• Marcovecchio L, Dalton R, Prevost A et al. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care 2009; 32: 658–663.
   PubMed Web of Science ®Google Scholar
• Perez A, Wagner A, Carreras G et al. Prevalence and phenotype distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control. Arch Intern Med 2000; 160: 2756–2762.
   Web of Science ®Google Scholar
• Willems D, Dorchy H. Lipoprotein and apolipoprotein levels in young insulin-dependent diabetic patients. Relations with glycosylated hemoglobin and fruc-tosamine. Presse Med 1990; 19: 17–20.
   Google Scholar
• Willems D, Dorchy H. Serum antioxidant status and oxidized LDL in well-controlled young type 1 diabetic patients with and without subclinical compli-cations. Atherosclerosis 1998; 137: S61–64.
   Web of Science ®Google Scholar
• Haffner S. Lipoprotein(a) and diabetes. An update. Diabetes Care 1993; 16: 835–840.
   Web of Science ®Google Scholar
• Ridker P, Hennekens C, Buring J, Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–843.
   PubMed Web of Science ®Google Scholar
• Coulon J, Willems D, Dorchy H. Increase in C-reactive protein plasma levels dur-ing diabetes in infants and young adults. Presse Med 2005; 34: 89–93.
   Web of Science ®Google Scholar
• Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. Circ J 2009; 73: 608–614.
   PubMed Web of Science ®Google Scholar
• Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930–1935.
   PubMed Web of Science ®Google Scholar
• Bacha F, Saad R, Gungor N, Arslanian S. Adiponectin in youth. Diabetes Care 2004; 24: 547–552.
   Google Scholar
• Costacou T, Zgibor J, Evans R et al. The prospective association between adi-ponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2005; 48:41–48.
   Web of Science ®Google Scholar
• Morales A, Wasserfall C, Brusko T et al. Adiponectin and leptin concentrations may aid in discriminating disease forms in children and adolescents with type 1 and type 2 diabetes. Diabetes Care 2004; 27: 2010–2014.
   PubMed Web of Science ®Google Scholar
• Li S, Shin H, Ding E, van Dam R. Adiponectin levels and risk of type 2 diabetes. A systematic review and meta-analysis. JAMA 2009; 302: 179–188.
   PubMed Web of Science ®Google Scholar
• Saraheimo M, Forsblom C, Fagerudd J et al. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 2005; 28: 1410–1414.
   PubMed Web of Science ®Google Scholar
• Milagros G. Adiponectin and leptin: potential tools in the differential diagnosis of pediatric diabetes? Rev Endocr Metab Disord 2006; 7: 187–196.
   Web of Science ®Google Scholar
• Dorchy H. Insulin regimens and injection adjustments in diabetic children, ado-lescents and young adults: personal experience. Diabetes Metab 2000; 26: 500–507.
   Web of Science ®Google Scholar
• Dorchy H. Treatment management in type 1 diabetes (insulin, diet, sport):“Dor-chy's recipes”. Rev Med Brux 2010; 31: S37–53.
   Google Scholar
• Dorchy H. Dietary management for children and adolescents with diabetes mel-litus: personal experience and recommendations. J Pediatr Endocrinol Metab 2003; 16: 131–148.
   Web of Science ®Google Scholar
• Cole T, Freeman J, Preece M. Body mass index reference curves for the UK, 1990. Arch Dis Child 1990; 73: 17–24.
   Google Scholar
• Dorchy H. What glycemic control can be achieved in young diabetics without residual secretion of endogenous insulin? What is the frequency of severe hypoglycemia and subclinical complications? Arch Pediatr 1994; 1: 970–981.
   PubMedGoogle Scholar
• The Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term com-plications in insulin dependent diabetes mellitus. N Engl J Med 1993: 329: 977–986.
   PubMed Web of Science ®Google Scholar
• Silverstein J, Klingensmith G, Copeland K. Care of children and adolescents with type 1 diabetes. A statement of the American Diabetes Association. Diabetes Care 2005; 28:186–212.
   PubMed Web of Science ®Google Scholar
• Aslander E, Smart C, Waldron S. ISPAD clinical practice consensus guidelines 2006-2007. Nutritional management in childhood and adolescent diabetes. Pediatr Diabetes 2007; 8:323–339.
   Web of Science ®Google Scholar
• National Cholesterol Education Program (NCPE): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89:495–501.
   PubMed Web of Science ®Google Scholar
• Williams K, Tchernof A, Hunt K, Wagenknecht L, Haffner S, Sniderman A. Diabe-tes, abdominal adiposity, and atherogenic dyslipoproteinemia in women com-pared with men. Diabetes 2008; 57: 3289–3296.
   PubMed Web of Science ®Google Scholar
• Goropashnaya A, Herron J, Sexton M et al. Relationship between plasma adi-ponectin and body fat distribution, insulin sensitivity, and plasma lipoproteins in Alaskan Yupik Eskimos: the Center for Alaska Native Health Research study. Metabolism 2009; 58: 22–29.
   Web of Science ®Google Scholar
• Rubin D, McMurray R, Harrell J, Hackney A, Haqq A. Do surrogate markers for adiposity relate to cytokines in adolescents? J Investig Med 2008; 56: 786–792.
   Web of Science ®Google Scholar
• Ruige J, Ballaux D, Funahashi T, Mertens I, Matsuzawa Y, Van Gaal L. Resting metabolic rate is an important predictor of serum adiponectin concentrations: potential implications for obesity-related disorders. Am J Clin Nutr 2005; 82: 21–25.
   Web of Science ®Google Scholar
• Bobbert T, Rochlitz H, Wegewitz U et al. Changes of adiponectin oligomer com-position by moderate weight reduction. Diabetes 2005; 54: 2712–2719.
   PubMed Web of Science ®Google Scholar